Algorae Pharmaceuticals (ASX:1AI) Total Current Assets : A$3.76 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Algorae Pharmaceuticals Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Algorae Pharmaceuticals's total current assets for the quarter that ended in Dec. 2023 was A$3.76 Mil.

Algorae Pharmaceuticals Total Current Assets Historical Data

The historical data trend for Algorae Pharmaceuticals's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algorae Pharmaceuticals Total Current Assets Chart

Algorae Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Current Assets

Get a 7-Day Free Trial

5.40

3.07

1.63

4.27

4.21

Algorae Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Current Assets	Get a 7-Day Free Trial															4.46	4.27	3.11	4.21	3.76

Algorae Pharmaceuticals Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Algorae Pharmaceuticals's Total Current Assets for the fiscal year that ended in Jun. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	4.111	+	0.096	+	0	+	0
	=	4.21

Algorae Pharmaceuticals's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	3.622	+	0.136	+	0	+	0
	=	3.76

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Algorae Pharmaceuticals (ASX:1AI) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Algorae Pharmaceuticals's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3.622	-	0.14	+	0.75 * 0.136	+	0.5 * 0
=	3.58

Algorae Pharmaceuticals Total Current Assets Related Terms

Thank you for viewing the detailed overview of Algorae Pharmaceuticals's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Algorae Pharmaceuticals (ASX:1AI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algorae Pharmaceuticals Ltd (ASX:1AI) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

LVCLY:USA LVCLF:USA LHI0:Germany

Address

201 Sussex Street, Level 16, Tower 2, Darling Park, Sydney, NSW, AUS, 2000

Website

https://www.algoraepharma.com

Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for undermet medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. Its lead products comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualised to be a potential treatment for dementia, including Alzheimer's disease; NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.

Algorae Pharmaceuticals (ASX:1AI) Headlines

No Headlines